Detalhe da pesquisa
1.
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Blood
; 141(20): 2493-2507, 2023 05 18.
Artigo
Inglês
| MEDLINE | ID: mdl-36302166
2.
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
Blood
; 137(7): 929-938, 2021 02 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32871586
3.
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
Br J Haematol
; 198(4): 684-692, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35567407
4.
Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia.
Br J Haematol
; 199(2): 230-238, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35961783
5.
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.
Blood
; 136(24): 2803-2811, 2020 12 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32603413
6.
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Blood
; 134(9): 761-764, 2019 08 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31300404
7.
COVID-19 and myeloma: what are the implications for now and in the future?
Br J Haematol
; 190(2): 173-178, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32428242
8.
CARs put age in the rearview mirror.
Blood
; 142(12): 1029-1031, 2023 09 21.
Artigo
Inglês
| MEDLINE | ID: mdl-37733380
9.
A tale of two antibodies: obinutuzumab versus rituximab.
Br J Haematol
; 182(1): 29-45, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29741753
10.
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
Curr Oncol Rep
; 20(12): 103, 2018 11 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30483893
11.
Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.
Cancers (Basel)
; 16(5)2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38473251
12.
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Leuk Lymphoma
; 65(3): 346-352, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38156444
13.
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy.
Transplant Cell Ther
; 30(3): 283.e1-283.e10, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38123069
14.
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
J Hematol Oncol
; 17(1): 42, 2024 Jun 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38845015
15.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Blood Adv
; 8(1): 251-259, 2024 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37855718
16.
Soft tissue plasmacytomas in multiple myeloma.
Lancet
; 390(10107): 2083, 2017 Nov 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28844475
17.
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
J Hematol Oncol
; 16(1): 88, 2023 07 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37525244
18.
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Clin Cancer Res
; 29(22): 4575-4585, 2023 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37735756
19.
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 41(25): 4164-4177, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37319384
20.
Relapse timing is associated with distinct evolutionary dynamics in DLBCL.
medRxiv
; 2023 Mar 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36945587